Effects of Discontinuing Renin-angiotensin System Inhibitors in Patients With and Without COVID-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

78 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-05-18

Study Completion Date

2022-12-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Recent data from some of the earliest and worst affected countries of COVID-19 suggest a major overrepresentation of hypertension and diabetes among COVID-19-related deaths and among patients experiencing severe courses of the disease. The vast majority of patients with hypertension and/or diabetes are taking drugs targeting the renin-angiotensin system (RAS) because of their blood pressure-lowering and/or kidney-protective effects. Importantly, the virus causing COVID-19, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) binds to the transmembrane protein angiotensin converting enzyme 2 (ACE2) - an important component of RAS - for host cell entry and subsequent viral replication. ACE2 is normally considered to be an enzyme that limits airway inflammation via effects in RAS and increased ACE2 activity seems to alleviate acute respiratory distress syndrome (ARDS). Importantly, evidence from human studies as well as rodent studies suggests that the inhibition of RAS by angiotensin converting enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARB) leads to upregulation of ACE2, and treatment with ARB leads to attenuation of SARS-CoV-induced ARDS. This is of interest, as the vast majority of deaths from COVID-19 are due to ARDS and expression of ACE2 has previously been shown to be reduced by the binding of SARS-CoV to ACE2. Thus, ACE inhibitors and ARBs have been suggested to alleviate the COVID-19 pulmonary manifestations. In contrast to these notions, concern has been raised that ACE2 upregulation (by RAS-inhibiting drugs) will multiply the cellular access points for viral entry and might increase the risk of severe progression of COVID-19. The multiplied viral entry points could perhaps explain the alarmingly high morbidity and mortality among COVID-19 patients with diabetes and/or hypertension. Thus, a delineation of the role of RAS for the course of COVID-19 is of crucial importance for the management of COVID-19 patients.

Aim:

This randomised clinical trial will investigate whether to continue or discontinue treatment with ACE inhibitors or ARBs in hospitalised patients with COVID-19.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Renin-Angiotensin System Inhibitors and COVID-19

NCT04331574

COVID-19 Hypertension Cardiovascular Diseases

UNKNOWN

Renin Angiotensin System - CoronaVirus

NCT04337008

COVID 19

UNKNOWN NA

Hypertension in Patients Hospitalized With COVID-19

NCT04318301

COVID-19 Hypertension

COMPLETED

Renin-Angiotensin-Aldosterone System Inhibitors, Hypertension, and COVID-19

NCT04374695

COVID-19

UNKNOWN

Renal Sympathectomy in Treatment Resistant Essential Hypertension, a Sham Controlled Randomized Trial

NCT01459900

Hypertension

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Covid-19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A: COVID+ Continuation

The enrolled patients will continue their prescribed ACEi/ARB in the same dose. The clinicians will be encouraged to continue the medication throughout the hospital admission but it will be permissable for the clinician to stop treatment if necessary e.g. due to hypotension.

Group Type EXPERIMENTAL

Continuation of ACEi/ARB

Intervention Type OTHER

Continuation of ACEi/ARB

B: Covid+ Discontinuation

The enrolled patients will discontinue their prescribed ACEi/ARB. If hypertensive treatment is necessary during hospital admission the clinicians will first be encouraged to start non-ACEi/non-ARB treatment; however, if needed it will be possible to start ACEi/ARB again during hospital admission. After study completion (30 days from randomization) the patients will be reminded to seek their generel practitioner to reinitiate ACEi/ARB treatment.

Group Type EXPERIMENTAL

Discontinuation of ACEi/ARB

Intervention Type OTHER

Discontinuation of ACEi/ARB

C: COVID% Continuation

The enrolled patients will continue their prescribed ACEi/ARB in the same dose.

Group Type EXPERIMENTAL

Continuation of ACEi/ARB

Intervention Type OTHER

Continuation of ACEi/ARB

D: COVID% DIscontinuation

The enrolled patients will discontinue their prescribed ACEi/ARB. If hypertensive treatment is necessary during the study period clinicians will first be encouraged to start non-ACEi/non-ARB treatment; however, if needed it will be possible to start ACEi/ARB again during the study period. After study completion (30 days from randomization) the patients will be reminded to seek their generel practitioner to reinitiate ACEi/ARB treatment.

Group Type EXPERIMENTAL

Discontinuation of ACEi/ARB

Intervention Type OTHER

Discontinuation of ACEi/ARB

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Discontinuation of ACEi/ARB

Intervention Type OTHER

Continuation of ACEi/ARB

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Verified COVID-19
2. Hospital admitted
3. Daily administration of RAS-inhibiting therapy
4. Age 18 years and above
5. Informed consent

1. Daily administration of RAS-inhibiting therapy
2. Age 18 years and above
3. Informed consent

Exclusion Criteria

1. Diagnosed with systolic heart failure (heart failure with reduced ejection fraction)
2. Severe kidney disease; defined by estimated glomerular filtration rate (eGFR) \<30 ml/min/1.73 m2
3. Severe hypertension; defined by systolic pressure \>175 mm Hg and/or diastolic pressure \>105 mm Hg
4. Hypotension; defined by systolic pressure \<100 mm Hg and/or diastolic pressure \<60 mm Hg
5. Non-compliance of RAS-inhibiting therapy; defined as an estimated adherence \<80% assessed by a questionnaire in combination with checking the Danish electronic medication system "FMK" (obligatory for clinicians in Denmark to ensure the Danish electronic medication system "FMK" is correct and up-to-date) for redeemed prescriptions in the last six months; in borderline cases, the participant is assumed compatible
6. Pregnancy or breastfeeding
7. Contra indications for receiving ACE inhibitors or ARBs:

1. Severe liver disease
2. Hypersensitivity or allergic reactions to the therapy
3. Angioneurotic edema during previous treatments
4. Family history of or previous idiopathic angioneurotic edema
5. Treatment with sacubitril/valsartan or aliskiren

Group C and D:

1. Diagnosed with systolic heart failure (heart failure with reduced ejection fraction)
2. Severe kidney disease; defined by estimated glomerular filtration rate (eGFR) \<30 ml/min/1.73 m2
3. Severe hypertension; defined by systolic pressure \>175 mm Hg and/or diastolic pressure \>105 mm Hg
4. Hypotension; defined by systolic pressure \<100 mm Hg and/or diastolic pressure \<60 mm Hg
5. Non-compliance of RAS-inhibiting therapy; defined as an estimated adherence \<80% assessed by a questionnaire in combination with checking the Danish electronic medication system "FMK" (obligatory for clinicians in Denmark to ensure the Danish electronic medication system "FMK" is correct and up-to-date) for redeemed prescriptions in the last six months; in borderline cases, the participant is assumed compatible
6. Pregnancy or breastfeeding
7. Contra indications for receiving ACE inhibitors or ARBs:

1. Severe liver disease
2. Hypersensitivity or allergic reactions to the therapy
3. Angioneurotic edema during previous treatments
4. Family history of or previous idiopathic angioneurotic edema
5. Treatment with sacubitril/valsartan or aliskiren

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No